LARP1 EGYR Peptide Detection for Reliable Biomarker Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting LARP1 protein in biological samples, particularly blood samples, are unreliable due to protein fragmentation and unpredictable levels over time, making it difficult to accurately quantify and monitor its presence and activity, which is crucial for cancer diagnosis and treatment response.
Innovation Solution
The method involves detecting the LARP1-derived EGYR peptide fragment using mass spectrometry after trypsin digestion and chromatographic separation, allowing for precise quantification by comparing the peptide levels to isotopically labeled standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Sandwich ELISA is used to detect LARP1 in circulation, then detection can be performed, but the levels are unpredictable and change over time due to protein fragmentation
Solution Approach 1:
The patent segments the LARP1 protein into a specific peptide fragment (EGYR, residues 24-27) for detection. By focusing on a discrete peptide sequence rather than the entire protein, the method achieves consistent and reliable detection despite the dynamic fragmentation of the full protein in circulation. This segmentation allows precise quantification of LARP1 through its stable peptide signature.
2Measurement precision
If mass spectrometry is used to detect EGYR peptide, then accurate quantification is achieved, but the method complexity increases
Solution Approach 1:
The patent extracts and isolates the specific EGYR peptide fragment from the complex mixture of blood proteins through targeted mass spectrometry. By extracting only the relevant peptide sequence (residues 24-27 of LARP1) for detection, the method achieves high quantification precision while managing system complexity through focused analysis rather than comprehensive proteomic profiling.
3Reliability
If LARP1 protein is detected in blood samples, then cancer biomarker identification is possible, but protein fragmentation causes unpredictable detection levels
Solution Approach 1:
The patent applies preliminary proteolytic digestion (e.g., trypsin treatment) to the blood sample before mass spectrometry analysis. This preliminary action stabilizes the protein composition by breaking down the unstable full-length LARP1 protein into consistent peptide fragments, including the EGYR sequence. This ensures reliable and reproducible detection of the biomarker while accounting for the fragmentation issue through controlled pre-treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable and accurate method for detecting and quantifying LARP1 protein levels, enabling effective cancer prognosis, treatment monitoring, and early cancer detection by correlating EGYR peptide levels with cancer progression and therapeutic response.
Implementation Method 1
LARP1 is required for malignant transformation of cells. It attaches to mRNAs to stabilise them so that they can over-produce oncoproteins.
Implementation Method 2
The invention relates to methods for quantitative measurement of LARP1 and LARP1-derived EGYR peptide by chromatography-tandem mass spectrometry.
Implementation Method 3
The invention relates to methods for quantitative measurement of LARP1 and LARP1-derived EGYR peptide by chromatography-tandem mass spectrometry.
Data Source
AI summary
The invention relates to the detection of EGYR peptide in a biological sample as a measure of the presence and/or amount of LARP1 protein in the sample. Suitably, the invention relates to methods for quantitative measurement of LARP1 and LARP1-derived EGYR peptide by chromatography-tandem mass spectrometry. The invention also relates to peptide standards and their use in quantitative mass spectrometric analyses. The ability to detect the amount of LARP1 in a biological sample has application in detecting and monitoring cancer.